These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 9710028

  • 1. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J.
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [Abstract] [Full Text] [Related]

  • 2. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, Swedish Parkinson Study Group.
    Neurology; 2006 Apr 25; 66(8):1200-6. PubMed ID: 16540603
    [Abstract] [Full Text] [Related]

  • 3. Selegiline as initial treatment in de novo parkinsonian patients.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Neurology; 1992 Feb 25; 42(2):339-43. PubMed ID: 1736162
    [Abstract] [Full Text] [Related]

  • 4. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH.
    Acta Neurol Scand; 1997 Apr 25; 95(4):211-8. PubMed ID: 9150811
    [Abstract] [Full Text] [Related]

  • 5. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov 25; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar 25; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 7. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.
    Neurology; 1998 Sep 25; 51(3):825-30. PubMed ID: 9748034
    [Abstract] [Full Text] [Related]

  • 8. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA.
    Acta Neurol Scand; 1995 Mar 25; 91(3):177-82. PubMed ID: 7793231
    [Abstract] [Full Text] [Related]

  • 9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S, Parkinson Study Group.
    J Neurol; 2005 Oct 25; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 25; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 11. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H, Pollak P, Neukirch HC.
    Mov Disord; 1993 Jul 25; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [Abstract] [Full Text] [Related]

  • 12. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Jul 25; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 13. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Acta Neurol Scand Suppl; 1991 Jul 25; 136():70-2. PubMed ID: 1801540
    [Abstract] [Full Text] [Related]

  • 14. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.
    Larsen JP, Boas J, Erdal JE.
    Eur J Neurol; 1999 Sep 25; 6(5):539-47. PubMed ID: 10457386
    [Abstract] [Full Text] [Related]

  • 15. Selegiline in de novo parkinsonian patients: the Finnish study.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Mov Disord; 1993 Sep 25; 8 Suppl 1():S41-4. PubMed ID: 8302307
    [Abstract] [Full Text] [Related]

  • 16. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM.
    Postgrad Med; 1996 Jan 25; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [Abstract] [Full Text] [Related]

  • 17. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
    Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N.
    Clin Neuropharmacol; 2010 Jan 25; 33(1):1-4. PubMed ID: 19935410
    [Abstract] [Full Text] [Related]

  • 18. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD.
    Drugs; 1998 Jan 25; 55 Suppl 1():23-30. PubMed ID: 9483167
    [Abstract] [Full Text] [Related]

  • 19. A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.
    Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.
    Clin Neuropharmacol; 2017 Jan 25; 40(5):201-207. PubMed ID: 28857772
    [Abstract] [Full Text] [Related]

  • 20. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
    Allain H, Cougnard J, Neukirch HC.
    Acta Neurol Scand Suppl; 1991 Jan 25; 136():73-8. PubMed ID: 1801541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.